COPZ2 and neoplasm: In order to corroborate the validity of COPZ1 as tumor target, further efforts should also be dedicated to assess if the effects of COPZ1 inhibition are context-specific or shared by different tumor type models, as well as to validate COPZ2 as a biomarker for patient stratification.